Zosuquidar Restores Drug Sensitivity in Acute Myeloid Leukemia
Author Information
Author(s): Tang Ruoping, Faussat Anne-Marie, Perrot Jean-Yves, Marjanovic Zora, Cohen Simy, Storme Thomas, Morjani Hamid, Legrand Ollivier, Marie Jean-Pierre
Primary Institution: INSERM, U872 Equipe 18 Paris
Hypothesis
Can zosuquidar reverse chemoresistance in acute myeloid leukemia (AML) by inhibiting P-glycoprotein?
Conclusion
Zosuquidar may be an effective adjunct to chemotherapy for AML patients whose blasts express P-glycoprotein, particularly in older patients.
Supporting Evidence
- Zosuquidar enhanced drug sensitivity in all P-gp-expressing leukemia cell lines tested.
- Zosuquidar was found to be more effective than cyclosporine A in enhancing cytotoxicity.
- 26% of AML cases showed enhanced drug cytotoxicity with zosuquidar.
- 71% of patients with active P-gp benefited from zosuquidar treatment.
Takeaway
Zosuquidar helps make cancer drugs work better in some leukemia patients by blocking a protein that pumps the drugs out of the cells.
Methodology
The study used flow cytometry to analyze protein expression and MTT assays to evaluate drug cytotoxicity in leukemia cell lines and primary AML blasts.
Potential Biases
Potential bias in patient selection and the effects of other treatments were not fully controlled.
Limitations
The study primarily focused on in vitro results and may not fully represent clinical outcomes.
Participant Demographics
The study included 31 AML patients, with a mean age of 60 years, and a significant portion were older than 60.
Statistical Information
P-Value
p<0.004
Statistical Significance
p<0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website